Market accessOfficial

SÚKL updates Czech IPLP list for 1 November with radiopharmaceutical and ATMP changes

🇨🇿 SÚKL · Fri 30 Oct 2026

The Czech medicines authority has published its November 2026 list of individually prepared medicinal products, incorporating two general-nature measures on radiopharmaceuticals and an advanced therapy medicinal product.

The State Institute for Drug Control (SÚKL) in the Czech Republic published on 30 October 2026 an updated list of individually prepared medicinal products (IPLP), together with other products whose reimbursement is set by a measure of general nature. The list takes effect on 1 November 2026.

The update incorporates two measures. Measure 07-26 (file reference SUKLS253478/2026) covers the group of individually prepared radiopharmaceuticals. Measure 08-26 (SUKLS214688/2026) concerns a medicinal product for advanced therapy. SÚKL says the changes were made under section 15(5) of Act No. 48/1997 Coll. on public health insurance.

The notice also restates how IPLP are coded. Because these products do not go through marketing authorisation, SÚKL uses the seven-digit code series that the Czech Ministry of Health created in 1991 for the sub-groups. When a new product is added to a sub-group, it receives the next number in that series. A code freed by a withdrawn product is not reused.

The notice describes several numbering conventions. Radiopharmaceuticals in sub-group 13 start at 0002XXX, with products added later prefixed by "5" (5002XXX). Transfusion products (sub-group 12) and autologous transfusion products (sub-group 15) are now also prefixed with "5", keeping the existing ranges, for example 5007XXX for erythrocyte products. Sub-group 16, advanced therapy medicinal products, continues in a series starting at 5600XXX. Tissues and cells (sub-group 17) are prefixed with 7.

SÚKL provides the full list as searchable spreadsheets and downloadable CSV and TXT files. It also provides separate files showing additions and removals against the previous list, dated 1 June 2026, as well as supporting code tables and explanatory documentation. The notice does not describe individual product changes.

What it means for your team

  • Market-access and reimbursement teams handling radiopharmaceuticals or advanced therapy products in Czechia should check the additions and removals files against the 1 June 2026 list.
  • Pharmacy and IT systems that rely on IPLP codes should be checked against the "5"-prefixed numbering for sub-groups 12, 13, 15 and 16.
  • The coding rules mean withdrawn codes are never reassigned, which matters for historical reporting and data mapping.

Official source: SÚKL ↗

Article written by VigiEye from the official source (SÚKL). AI-assisted; check the source before acting.

More Market access All →